Persista Bio Receives Positive Feedback on Modular Approach from FDA INTERACT

RegulatorypositivePositive

AI Analysis

Summary

Persista Bio received positive FDA feedback on its modular cell therapy system approach for Type 1 diabetes through an INTERACT meeting with CBER, increasing confidence in the development strategy.

Outcome Details

Positive feedback on modular approach to cell therapy system for Type 1 diabetes

Importance:6/10

Sentiment:

0.70

cell therapyType 1 diabetesFDA INTERACTmodular approach

Read the original article

Published by PR Newswire Biotech on September 23, 2026 12:36 PM

Read Original